Abstract 428P
Background
Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm with an intermediate biologic potential. The aim of this study was to investigate clinical and pathological factors as well as peripheral blood counts to determine factors predicting for likelihood of early recurrence and poor survival in extra-meningeal SFTs after surgical resection.
Methods
We retrieved the records of 101 patients that were consecutively diagnosed with SFT from 1996-2019 at the National Cancer Centre Singapore and Singapore General Hospital. 19 patients were excluded from the study, of which 6 had distant metastasis at diagnosis, 5 did not undergo curative surgery and 8 were meningeal SFTs that are known to have a poor prognosis. The remaining 82 cases of extra-meningeal SFTs that underwent curative surgery were retrospectively examined with survival analyses performed using the Kaplan-Meier method and multivariate Cox proportional models.
Results
The cohort consisted of 37 men and 45 women with a median age of 51 years (range, 13-87). The primary site of the tumour was abdominopelvic in 18 (22.0%), limbs/trunk in 27 (32.9%), pulmonary/pleura in 18 (22.0%) and head/neck in 19 (23.2%). Median tumour size was 5.0 cm (range, 1.4-30.0). The 5-year overall survival (OS) and event-free survival (EFS) was 92.4% and 79.2% respectively. On univariate analysis, advanced age was prognostic for worse OS, while an abdominopelvic site, lymphocytosis (>2.2 x 109/L) and monocytosis (>0.56 x 109/L) were prognostic for both worse OS and EFS. On multivariate analysis, only age, abdominopelvic site and monocytosis remained independently prognostic for OS, while abdominopelvic site and monocytosis were retained as independently prognostic factors for EFS (all p < 0.05). Tumour depth, tumour size, resection margin, tumour necrosis and mitotic count were not significantly prognostic.
Conclusions
In extra-meningeal SFT, clinical factors including advanced age and abdominopelvic location indicate poor prognosis. In addition, peripheral monocytosis at diagnosis may serve as a novel and easily obtained biomarker for further prognostication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session